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I quote the editors reference in the introduction ‘A single
laboratory or a small team of researchers can no longer
successfully accomplish drug development. Rather there is a
complex interplay among the drug discovery staff, the preclinical
formulation group, toxicology and metabolism, the analytic group,
large scale purification or synthesis, the clinical group and
regulatory affairs.’ By quoting this, I believe, the authors have
strived to achieve the best book of reference that integrates every
aspect of anticancer drug development and they have succeeded in
their effort. The authors have put forth four major objectives
behind this book: (1) to identify potential pitfalls and pathways
useful in drug development, (2) discuss methods to make
preclinical and clinical process more efficient and safe, (3) let
the contents of the book serve as a paradigm to rational
approaches to much of drug development and (4) discuss how
the complexity and nature of malignancy complicates and diverges
the clinical development. All of the above objectives are well met in
this book. Controversies exist in every field of research and the
authors have clearly made a note of it and have included the
contradicting interpretations and conclusions from individual
contributors to keep the reader informed about the limitations of
current knowledge.
This book consists of 33 chapters in eight independent parts
covering various details of drug discovery and development
through regulatory requirements for licensure. The general layout
of the book is well done and the book focuses on the fundamental
issues that are important to understanding and establishing a
successful anticancer drug development programme. The book
starts with an introduction as Part 1. Part 2 focuses on Drug
Discovery, the basic and the most well done part of all covering hot
topics like Proteomics, Bioinformatics and Data mining. Protein
crystallography in drug discovery is the future and a dedicated
chapter to it is commendable. Preclinical models, analytical
techniques and delivery systems are discussed under Part 3, 4
and 5. Nanoparticle technology is emerging as a cutting-edge
technology in drug development. A separate chapter on this
technology would have added spice to this book. Clinical studies
are briefed in Part 6. Of special interest is Part 7 that addresses
certain specific issues in drug development that are not widely
discussed otherwise. A quick coverage of regulatory issues is listed
under Part 8. As and when needed, a simultaneous comparison of
the industry practices in US and elsewhere reveals the meticulous
efforts by the editors to cover as much information as possible in a
more comprehensive way.
There are however certain shortcomings that probably are
specific to the individual contributors. For example, Chapter 2
begins with a brief overview of the advantages of the natural
environment as a rich source of natural compounds highlighting
how some of the key factors like supply of material, purity,
solubility, etc. result in protracted development of these com-
pounds. Given such a lucid introduction, one would except to
understand the magnitude of such factors in terms of specific
examples and ways to overcome such problems to expedite the
successful drug development. On the contrary, the authors have
more reviewed the mechanistic aspects of specific agents grouped
under three different categories, marine-, plant- and microbial-
derived agents.
In summary, the book is a comprehensive representation of the
overall anticancer drug developmental process and regulatory
guidance essential to understanding drug development. The book
is truly a ‘Handbook’ for anyone interested in or involved in
anticancer drug development. Editors Daniel R Budman, Alan H
Calvert and Eric K Rowinsky should be commended for their
contribution to this evergrowing and challenging field of research
and patient care.
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